Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jian-Qing Mi is active.

Publication


Featured researches published by Jian-Qing Mi.


Nature Genetics | 2011

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

Xiao-Jing Yan; Jie Xu; Zhao-Hui Gu; Chun-Ming Pan; Gang Lu; Yang Shen; Jing-Yi Shi; Yong-Mei Zhu; Lin Tang; Xiao-Wei Zhang; Wen-Xue Liang; Jian-Qing Mi; Huai-Dong Song; Ke-Qin Li; Zhu Chen; Sai-Juan Chen

Abnormal epigenetic regulation has been implicated in oncogenesis. We report here the identification of somatic mutations by exome sequencing in acute monocytic leukemia, the M5 subtype of acute myeloid leukemia (AML-M5). We discovered mutations in DNMT3A (encoding DNA methyltransferase 3A) in 23 of 112 (20.5%) cases. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Notably, there were alterations of DNA methylation patterns and/or gene expression profiles (such as HOXB genes) in samples with DNMT3A mutations as compared with those without such changes. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset and of promonocytic as well as monocytic predominance among AML-M5 individuals. Screening other leukemia subtypes showed Arg882 alterations in 13.6% of acute myelomonocytic leukemia (AML-M4) cases. Our work suggests a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases.


Cancer Cell | 2010

PML/RARα Targets Promoter Regions Containing PU.1 Consensus and RARE Half Sites in Acute Promyelocytic Leukemia

Kankan Wang; Ping Wang; Jiantao Shi; Xuehua Zhu; Miaomiao He; Xiaohong Jia; Xianwen Yang; Fei Qiu; Wen Jin; Maoxiang Qian; Hai Fang; Jian-Qing Mi; Xuzhi Yang; Huasheng Xiao; Mark D. Minden; Yanzhi Du; Zhu Chen; Ji Zhang

PML/RARalpha is of crucial importance in acute promyelocytic leukemia (APL) both pathologically and therapeutically. Using a genome-wide approach, we identified in vivo PML/RARalpha binding sites in a PML/RARalpha-inducible cell model. Of the 2979 targeted regions, >62% contained canonical PU.1 motifs and >84% of these PU.1 motifs coexisted with one or more RARE half (RAREh) sites in nearby regions. Promoters with such PU.1-RAREh binding sites were transactivated by PU.1. PU.1-mediated transactivation was repressed by PML/RARalpha and restored by the addition of all-trans retinoic acid (ATRA). Genes containing such promoters were significantly represented by genes transcriptionally suppressed in APL and/or reactivated upon treatment with ATRA. Thus, selective targeting of PU.1-regulated genes by PML/RARalpha is a critical mechanism for the pathogenesis of APL.


Proceedings of the National Academy of Sciences of the United States of America | 2011

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice

Yue-Ying Wang; Li-Juan Zhao; Chuan-Feng Wu; Ping Liu; Shi L; Yang Liang; Shu-Min Xiong; Jian-Qing Mi; Zhu Chen; Ruibao Ren; Sai-Juan Chen

The full-length AML1-ETO (AE) fusion gene resulting from t(8;21)(q22;q22) in human acute myeloid leukemia (AML) is not sufficient to induce leukemia in animals, suggesting that additional mutations are required for leukemogenesis. We and others have identified activating mutations of C-KIT in nearly half of patients with t(8;21) AML. To test the hypothesis that activating C-KIT mutations cooperate with AE to cause overt AML, we generated a murine transduction and transplantation model with both mutated C-KIT and AE. To overcome the intracellular transport block of human C-KIT in murine cells, we engineered hybrid C-KIT (HyC-KIT) by fusing the extracellular and transmembrane domains of the murine c-Kit in-frame to the intracellular signaling domain of human C-KIT. We showed that tyrosine kinase domain mutants HyC-KIT N822K and D816V, as well as juxtamembrane mutants HyC-KIT 571+14 and 557-558Del, could transform murine 32D cells to cytokine-independent growth. The protein tyrosine kinase inhibitor dasatinib inhibited the proliferation of 32D cells expressing these C-KIT mutants, with potency in the low nanomolar range. In mice, HyC-KIT N822K induced a myeloproliferative disease, whereas HyC-KIT 571+14 induces both myeloproliferative disease and lymphocytic leukemia. Interestingly, coexpression of AE and HyC-KIT N822K led to fatal AML. Our data have further enriched the two-hit model that abnormalities of both transcription factor and membrane/cytosolic signaling molecule are required in AML pathogenesis. Furthermore, dasatinib prolonged lifespan of mice bearing AE and HyC-KIT N822K-coexpressing leukemic cells and exerted synergic effects while combined with cytarabine, thus providing a potential therapeutic for t(8;21) leukemia.


Blood | 2014

A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value

Wen-Lian Chen; Jing-Han Wang; Aihua Zhao; Xin Xu; Yihuang Wang; Tianlu Chen; Junmin Li; Jian-Qing Mi; Yong-Mei Zhu; Yuan-Fang Liu; Yue-Ying Wang; Jie Jin; He Huang; Depei Wu; Yan Li; Xiao-Jing Yan; Jin-Song Yan; Jianyong Li; Shuai Wang; Xiao-Jun Huang; Bing-Shun Wang; Zhu Chen; Sai-Juan Chen; Wei Jia

Acute myeloid leukemia (AML) is a group of hematological malignancies with high heterogeneity. There is an increasing need to improve the risk stratification of AML patients, including those with normal cytogenetics, using molecular biomarkers. Here, we report a metabolomics study that identified a distinct glucose metabolism signature with 400 AML patients and 446 healthy controls. The glucose metabolism signature comprises a panel of 6 serum metabolite markers, which demonstrated prognostic value in cytogenetically normal AML patients. We generated a prognosis risk score (PRS) with 6 metabolite markers for each patient using principal component analysis. A low PRS was able to predict patients with poor survival independently of well-established markers. We further compared the gene expression patterns of AML blast cells between low and high PRS groups, which correlated well to the metabolic pathways involving the 6 metabolite markers, with enhanced glycolysis and tricarboxylic [corrected] acid cycle at gene expression level in low PRS group. In vitro results demonstrated enhanced glycolysis contributed to decreased sensitivity to antileukemic agent arabinofuranosyl cytidine (Ara-C), whereas inhibition of glycolysis suppressed AML cell proliferation and potentiated cytotoxicity of Ara-C. Our study provides strong evidence for the use of serum metabolites and metabolic pathways as novel prognostic markers and potential therapeutic targets for AML.


Proceedings of the National Academy of Sciences of the United States of America | 2013

Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China

Jing-Han Wang; Wen-Lian Chen; Jing Li; Song-Fang Wu; Tianlu Chen; Yong-Mei Zhu; Wei Zhang; Yanxin Li; Yunping Qiu; Aimin Zhao; Jian-Qing Mi; Jie Jin; Yungui Wang; Ma Ql; He Huang; Depei Wu; Wang Qr; Xiao-Jing Yan; Jin-Song Yan; Li Jy; Shuai Wang; Xu Huang; Bai-Yan Wang; Weiping Jia; Yiping Shen; Zi-Jiang Chen; Shi Chen

Significance Acute myeloid leukemia (AML) consists of a group of hematopoietic malignancies with considerable diversities in clinical and biological features. Recently, not only genetic abnormalities but also “oncometabolites,” such as 2-hydroxyglutarate (2-HG), have been found to play a role in driving AML pathogenesis and serve as potential disease markers. In this study on a large cohort of AML, we found that the serum 2-HG level was increased in 62 of 367 (17%) cases with distinct hematologic and biological features. Survival analysis performed in 234 patients without prognostic cytogenetic markers showed that increased 2-HG level was a poor predictor, demonstrating the potential of serum 2-HG as an independent marker for outcome evaluation of AML. The 2-hydroxyglutarate (2-HG) has been reported to result from mutations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes and to function as an “oncometabolite.” To evaluate the clinical significance of serum 2-HG levels in hematologic malignancies, acute myeloid leukemia (AML) in particular, we analyzed this metabolite in distinct types of human leukemia and lymphoma and established the range of serum 2-HG in appropriate normal control individuals by using gas chromatograph–time-of-flight mass spectrometry. Aberrant serum 2-HG pattern was detected in the multicenter group of AML, with 62 of 367 (17%) patients having 2-HG levels above the cutoff value (2.01, log2-transformed from 4.03 μg/mL). IDH1/2 mutations occurred in 27 of 31 (87%) AML cases with very high 2-HG, but were observed only in 9 of 31 (29%) patients with moderately high 2-HG, suggesting other genetic or biochemical events may exist in causing 2-HG elevation. Indeed, glutamine-related metabolites exhibited a pattern in favor of 2-HG synthesis in the high 2-HG group. In AML patients with cytogenetically normal AML (n = 234), high 2-HG represented a negative prognostic factor in both overall survival and event-free survival. Univariate and multivariate analyses confirmed high serum 2-HG as a strong prognostic predictor independent of other clinical and molecular features. We also demonstrated distinct gene-expression/DNA methylation profiles in AML blasts with high 2-HG compared with those with normal ones, supporting a role that 2-HG plays in leukemogenesis.


Blood | 2008

RGT, a synthetic peptide corresponding to the integrin β3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin αIIbβ3 with Src kinase

Xiaoyu Su; Jian-Qing Mi; Jingsong Yan; Panagiotis Flevaris; Yuanjing Lu; Hongchen Liu; Zheng Ruan; Xuefeng Wang; Nelly Kieffer; Sai-Juan Chen; Xiaoping Du; Xiaodong Xi

Mutational analysis has established that the cytoplasmic tail of the integrin beta 3 subunit binds c-Src (termed as Src in this study) and is critical for bidirectional integrin signaling. Here we show in washed human platelets that a cell-permeable, myristoylated RGT peptide (myr-RGT) corresponding to the integrin beta 3 C-terminal sequence dose-dependently inhibited stable platelet adhesion and spreading on immobilized fibrinogen, and fibrin clot retraction as well. Myr-RGT also inhibited the aggregation-dependent platelet secretion and secretion-dependent second wave of platelet aggregation induced by adenosine diphosphate, ristocetin, or thrombin. Thus, myr-RGT inhibited integrin outside-in signaling. In contrast, myr-RGT had no inhibitory effect on adenosine diphosphate-induced soluble fibrinogen binding to platelets that is dependent on integrin inside-out signaling. Furthermore, the RGT peptide induced dissociation of Src from integrin beta 3 and dose-dependently inhibited the purified recombinant beta 3 cytoplasmic domain binding to Src-SH3. In addition, phosphorylation of the beta 3 cytoplasmic tyrosines, Y(747) and Y(759), was inhibited by myr-RGT. These data indicate an important role for beta 3-Src interaction in outside-in signaling. Thus, in intact human platelets, disruption of the association of Src with beta 3 and selective blockade of integrin alpha IIb beta 3 outside-in signaling by myr-RGT suggest a potential new antithrombotic strategy.


EBioMedicine | 2016

Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia.

Yuan-Fang Liu; Bai-Yan Wang; Wei-Na Zhang; Jin-Yan Huang; Benshang Li; Ming Zhang; Lu Jiang; Jian-Feng Li; Wang Mq; Yu-Jun Dai; Z. Zhang; Qiang Wang; Jie Kong; Bing Chen; Yong-Mei Zhu; Xiang-Qin Weng; Zhi-Xiang Shen; Junmin Li; Jin Wang; Xiao-Jing Yan; Yan Li; Yingmin Liang; Li Liu; Xie-Qun Chen; Wang-Gang Zhang; Jin-Song Yan; Jianda Hu; Shuhong Shen; Jing Chen; Long-Jun Gu

Genomic landscapes of 92 adult and 111 pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) were investigated using next-generation sequencing and copy number alteration analysis. Recurrent gene mutations and fusions were tested in an additional 87 adult and 93 pediatric patients. Among the 29 newly identified in-frame gene fusions, those involving MEF2D and ZNF384 were clinically relevant and were demonstrated to perturb B-cell differentiation, with EP300-ZNF384 inducing leukemia in mice. Eight gene expression subgroups associated with characteristic genetic abnormalities were identified, including leukemia with MEF2D and ZNF384 fusions in two distinct clusters. In subgroup G4 which was characterized by ERG deletion, DUX4-IGH fusion was detected in most cases. This comprehensive dataset allowed us to compare the features of molecular pathogenesis between adult and pediatric B-ALL and to identify signatures possibly related to the inferior outcome of adults to that of children. We found that, besides the known discrepancies in frequencies of prognostic markers, adult patients had more cooperative mutations and greater enrichment for alterations of epigenetic modifiers and genes linked to B-cell development, suggesting difference in the target cells of transformation between adult and pediatric patients and may explain in part the disparity in their responses to treatment.


Blood | 2010

An evolutionarily conserved PTEN-C/EBPα-CTNNA1 axis controls myeloid development and transformation

Chun-Tang Fu; Kang-Yong Zhu; Jian-Qing Mi; Yuan-Fang Liu; Susan T. Murray; Yan-Fang Fu; Chun-Guang Ren; Zhi-Wei Dong; Yi-Jie Liu; Mei Dong; Yi Jin; Yi Chen; Min Deng; Wu Zhang; Bin Chen; Peter Breslin; Sai-Juan Chen; Zhu Chen; Michael W. Becker; Jiang Zhu; Jiwang Zhang; Ting Xi Liu

Loss of function of tumor suppressor genes, such as PTEN, CEBPAlpha, and CTNNA1 (encoding the alpha-catenin protein), has been found to play an essential role in leukemogenesis. However, whether these genes genetically interact remains largely unknown. Here, we show that PTEN-mammalian target of rapamycin signaling acts upstream to dictate the ratio of wild-type p42 C/EBPalpha to its dominant-negative p30 isoform, which critically determines whether p30 C/EBPalpha (lower p42/p30 ratio) or p42 C/EBPalpha (higher p42/p30 ratio) binds to the proximal promoter of the retained CTNNA1 allele. Binding of p30 C/EBPalpha recruits the polycomb repressive complex 2 to suppress CTNNA1 transcription through repressive H3K27me3 modification, whereas binding of p42 C/EBPalpha relieves this repression and promotes CTNNA1 expression through activating H3K4me3 modification. Loss of Pten function in mice and zebrafish induces myelodysplasia with abnormal invasiveness of myeloid progenitors accompanied by significant reductions in both wild-type C/EBPalpha and alpha-catenin protein. Importantly, frame-shift mutations in either PTEN or CEBPA were detected exclusively in the primary LICs with low CTNNA1 expression. This study uncovers a novel molecular pathway, PTEN-C/EBPalpha-CTNNA1, which is evolutionarily conserved and might be therapeutically targeted to eradicate LICs with low CTNNA1 expression.


Proceedings of the National Academy of Sciences of the United States of America | 2013

Preferential eradication of acute myelogenous leukemia stem cells by fenretinide.

Hui Zhang; Jian-Qing Mi; Hai Fang; Zhao Wang; Chun Wang; Lin Wu; Bin Zhang; Mark D. Minden; Wentao Yang; Huanwei Wang; Junmin Li; Xiao-Dong Xi; Sai-Juan Chen; Ji Zhang; Zhu Chen; Kankan Wang

Leukemia stem cells (LSCs) play important roles in leukemia initiation, progression, and relapse, and thus represent a critical target for therapeutic intervention. However, relatively few agents have been shown to target LSCs, slowing progress in the treatment of acute myelogenous leukemia (AML). Based on in vitro and in vivo evidence, we report here that fenretinide, a well-tolerated vitamin A derivative, is capable of eradicating LSCs but not normal hematopoietic progenitor/stem cells at physiologically achievable concentrations. Fenretinide exerted a selective cytotoxic effect on primary AML CD34+ cells, especially the LSC-enriched CD34+CD38− subpopulation, whereas no significant effect was observed on normal counterparts. Methylcellulose colony formation assays further showed that fenretinide significantly suppressed the formation of colonies derived from AML CD34+ cells but not those from normal CD34+ cells. Moreover, fenretinide significantly reduced the in vivo engraftment of AML stem cells but not normal hematopoietic stem cells in a nonobese diabetic/SCID mouse xenotransplantation model. Mechanistic studies revealed that fenretinide-induced cell death was linked to a series of characteristic events, including the rapid generation of reactive oxygen species, induction of genes associated with stress responses and apoptosis, and repression of genes involved in NF-κB and Wnt signaling. Further bioinformatic analysis revealed that the fenretinide–down-regulated genes were significantly correlated with the existing poor-prognosis signatures in AML patients. Based on these findings, we propose that fenretinide is a potent agent that selectively targets LSCs, and may be of value in the treatment of AML.


Journal of Proteome Research | 2013

Rapid Diagnosis and Prognosis of de novo Acute Myeloid Leukemia by Serum Metabonomic Analysis

Yihuang Wang; Limin Zhang; Wen-Lian Chen; Jing-Han Wang; Ning Li; Junmin Li; Jian-Qing Mi; Wei-Na Zhang; Yang Li; Song-Fang Wu; Jie Jin; Yungui Wang; He Huang; Zhu Chen; Sai-Juan Chen; Huiru Tang

Acute myeloid leukemia (AML) is a life-threatening hematological disease. Novel diagnostic and prognostic markers will be essential for new therapeutics and for significantly improving the disease prognosis. To characterize the metabolic features associated with AML and search for potential diagnostic and prognostic methods, here we analyzed the phenotypic characteristics of serum metabolite composition (metabonome) in a cohort of 183 patients with de novo acute myeloid leukemia together with 232 age- and gender-matched healthy controls using (1)H NMR spectroscopy in conjunction with multivariate data analysis. We observed significant serum metabonomic differences between AML patients and healthy controls and between AML patients with favorable and intermediate cytogenetic risks. Such differences were highlighted by systems differentiations in multiple metabolic pathways including glycolysis/gluconeogenesis, TCA cycle, biosynthesis of proteins and lipoproteins, and metabolism of fatty acids and cell membrane components, especially choline and its phosphorylated derivatives. This demonstrated the NMR-based metabonomics as a rapid and less invasive method for potential AML diagnosis and prognosis. The serum metabolic phenotypes observed here indicated that integration of metabonomics with other techniques will be useful for better understanding the biochemistry of pathogenesis and progression of leukemia.

Collaboration


Dive into the Jian-Qing Mi's collaboration.

Top Co-Authors

Avatar

Sai-Juan Chen

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Zhu Chen

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Junmin Li

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Hongming Zhu

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Jiong Hu

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Wei-Li Zhao

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Wei-Na Zhang

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Yong-Mei Zhu

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Zhi-Xiang Shen

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Bing Chen

Shanghai Jiao Tong University

View shared research outputs
Researchain Logo
Decentralizing Knowledge